The Cost of Waiting: The Economic Impact of Delayed Respiratory Diagnosis
July 23rd, 2026
Delays in diagnosis remain a persistent challenge across many respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD). In the UK, the scale of the problem is particularly evident in COPD, where around one in four people wait approximately five years for a diagnosis, while an estimated two million people may be living with undiagnosed disease [1].
These delays are largely driven by the non-specific nature of early symptoms such as breathlessness, persistent cough and fatigue, which are often attributed to ageing, smoking or reduced physical fitness. Fragmented diagnostic pathways, variability in recognising early disease, and limited access to specialist testing further contribute to delayed diagnosis. Consequently, many patients are only diagnosed once significant disease progression has occurred, by which time healthcare utilisation has increased [2].
As the prevalence of respiratory conditions continues to rise, reducing diagnostic delay will be essential not only for improving patient outcomes but also for ensuring the long-term sustainability of healthcare services. This article explores the consequences of delayed respiratory diagnosis, examines its economic impact, and highlights strategies being used to enable earlier detection and more efficient care delivery.
The Consequences for Patients
Respiratory diseases frequently present with symptoms that are non-specific, intermittent or slow to develop, making early recognition challenging. Delays in investigation and referral allow disease to progress before appropriate treatment can begin, increasing the risk of irreversible lung damage, acute exacerbations and avoidable complications [2].
For progressive respiratory diseases such as COPD and ILD, delayed diagnosis allows disease to advance before appropriate treatment is initiated, increasing the risk of irreversible lung damage, worsening symptoms and avoidable exacerbations. Earlier diagnosis enables treatment to begin sooner, helping preserve lung function, improve quality of life and reduce future healthcare utilisation [2].
Beyond the physical consequences, delayed diagnosis can have a significant impact on a patient's quality of life. Living with persistent but unexplained symptoms can lead to anxiety, uncertainty and repeated healthcare visits before an underlying cause is identified. It may also affect employment, independence and everyday activities, creating wider social and economic consequences.
The Economic Impact on Healthcare Services
Delayed respiratory diagnosis places considerable pressure on healthcare services through increased and often avoidable resource use. Patients typically require multiple GP consultations, investigations and referrals before a diagnosis is confirmed. For example, around 30% of ILD patients visit their GP on at least four separate occasions before referral to a specialist [3]. This extended diagnostic journey increases demand on primary care services, while also delaying access to appropriate treatment.
The impact extends into secondary care. Respiratory disease is the leading cause of emergency hospital admission in England, accounting for around one in eight emergency admissions [4]. COPD alone results in approximately 130,000 hospital admissions each year in the UK, many of which are associated with exacerbations that may be reduced through earlier diagnosis and better disease management [2].
These delays translate into substantial healthcare costs. The NHS spent more than £3.2 billion on respiratory hospital admissions in England in 2024, with almost 89% of this expenditure relating to emergency admissions [4]. Hospital admissions therefore represent one of the largest drivers of respiratory healthcare costs, highlighting the value of preventing disease progression before acute deterioration occurs.
As disease progresses, treatment becomes more complex and resource intensive. Patients with advanced respiratory disease may require specialist interventions, long-term oxygen therapy, frequent hospital follow-up or prolonged inpatient stays. This shift from early management to late-stage care significantly increases overall costs [2]..
Strategies to Improve Early Detection
Reducing diagnostic delay requires improvements throughout the respiratory care pathway. Raising awareness of persistent symptoms such as breathlessness, chronic cough and unexplained fatigue can encourage earlier presentation, while supporting primary care clinicians to recognise early disease can speed up investigation and referral.
Improving access to diagnostic tests, including spirometry, lung function assessment and imaging, alongside targeted case-finding in high-risk populations, can help identify disease earlier. Digital technologies, such as clinical decision support systems, predictive analytics and remote physiological monitoring, also have the potential to streamline diagnosis and enable earlier intervention.
Conclusion
Delayed respiratory diagnosis has wide-ranging consequences for patients and healthcare systems. It contributes to disease progression, increased healthcare utilisation and higher long-term costs. Earlier diagnosis offers the opportunity to improve outcomes through timely treatment while reducing avoidable healthcare utilisation and making more efficient use of NHS resources. As demand for respiratory care continues to rise, improving diagnostic pathways will be essential to reducing the cost of waiting and delivering both clinical and economic benefit.
References
[1] Asthma + Lung UK. A quarter of people with COPD waiting 5 years for a diagnosis [Internet]. 2022 [cited 2026 Jun 30]. Available from: https://www.asthmaandlung.org.uk/media/press-releases/quarter-people-copd-waiting-5-years-diagnosis.
[2] National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline Your responsibility [Internet]. 2018. Available from: www.nice.org.uk/guidance/ng115.
[3] Case AH, Beegle S, Hotchkin DL, et al. Defining the pathway to timely diagnosis and treatment of interstitial lung disease: a US Delphi survey. BMJ Open Respir Res. 2023;10(1):e001594.
[4] Asthma + Lung UK. Emergency admissions for breathing difficulties soar by almost half a million [Internet]. 2025 [cited 2026 Jul 11]. Available from: https://www.asthmaandlung.org.uk/media/press-releases/emergency-admissions-breathing-difficulties-soar-almost-half-million?utm_source=chatgpt.com.